Drug Discovery World
APRIL 9, 2024
A study by researchers at the UCLA Health Jonsson Comprehensive Cancer Center in the US suggests that injecting engineered dendritic cells directly into cancerous lung tumours can help promote a stronger immune response.
pharmaphorum
FEBRUARY 18, 2021
Researchers from the University of Texas Medical Branch based their findings on lab tests using SARS-CoV-2 coronaviruses that were genetically engineered to have the same mutations as those in the strain that is causing scientists so much concern.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JULY 5, 2023
A fulfilling part of my job is meeting the scientists, companies, and institutions at the forefront of ground-breaking research that are advancing patient health outcomes. The European Commission notes that whilst Europeans only make up one tenth of the global population, 25% of annual cancer cases fall within Europe.
Cloudbyz
MARCH 5, 2024
They are often used to mimic or enhance natural biological processes, such as immune responses. Immunogenicity : Small Molecules: Generally have a lower risk of inducing an immune response in the body. In this endeavor, collaboration between scientists, regulatory bodies, healthcare providers, and patients will be key.
pharmaphorum
MARCH 10, 2021
The study suggests that serum taken from patients injected with the mRNA shot, also known as BNT162b2, was able to neutralise a genetically engineered version of SARS-CoV-2 with the P.1 1 – that is worrying health officials around the world. . 1 mutations, as well as variants from the UK and South Africa.
The Pharma Data
JUNE 1, 2022
Blocking an immune response-related enzyme holds promise in preventing or treating severe COVID-19 symptoms by reducing inflammation, tissue injury and blood clots in the lungs, new research in mice suggests. Previous research has shown that caspase 11 in mice has many of the same immune-response functions as caspase 4 in humans.
Drug Discovery World
FEBRUARY 3, 2023
One of these candidates is VSV-SUDV, developed and tested by scientists at NIH’s National Institute of Allergy and Infectious Diseases in Hamilton, Montana. The fact that four control animals got sick demonstrates that pre-existing immunity to EBOV and VSV-EBOV has limited effect on protection from SUDV.
Expert insights. Personalized for you.
52 
Let's personalize your content